Document Detail


Prediction of response of patients with acute nonlymphocytic leukaemia to remission induction therapy: use of clinical measurements.
MedLine Citation:
PMID:  3460626     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Two hundred patients with acute nonlymphocytic leukaemia received remission induction therapy consisting of cytosine arabinoside and an anthracycline antibiotic. Analysis of the pretherapy characteristics of the patients demonstrated that patient age was the most important factor in determining whether or not the patient would survive remission induction therapy. Assessment of the characteristics of the bone marrow after 6 d of therapy permitted the recognition of patients who were likely to fail to enter remission because of persistent leukaemia. Taken together, these observations demonstrate that it is possible to identify patients for whom conventional chemotherapy is not likely to be of benefit either because it is too intensive or because it is not intensive enough to produce a complete remission.
Authors:
H D Preisler; R Priore; N Azarnia; M Barcos; A Raza; I Rakowski; R Vogler; E L Winton; G Browman; J Goldberg
Related Documents :
9031616 - Behçet's disease in patients with chronic myelogenous leukemia: possible role of interf...
9845546 - Incidence of tel/aml1 fusion in children with relapsed acute lymphoblastic leukemia.
18055346 - Neutropenic enterocolitis in children with acute leukemia or aplastic anemia.
17268486 - New therapeutic strategies for the treatment of acute lymphoblastic leukaemia.
22711036 - Biofeedback is an effective treatment for patients with dyssynergic defaecation.
24092596 - Patient-reported outcome measures in safety event reporting: prosper consortium guidance.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  British journal of haematology     Volume:  63     ISSN:  0007-1048     ISO Abbreviation:  Br. J. Haematol.     Publication Date:  1986 Aug 
Date Detail:
Created Date:  1986-09-25     Completed Date:  1986-09-25     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0372544     Medline TA:  Br J Haematol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  625-36     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Age Factors
Antibiotics, Antineoplastic / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bone Marrow / pathology
Cytarabine / administration & dosage
Humans
Leukemia / drug therapy*,  pathology
Middle Aged
Naphthacenes / administration & dosage
Prognosis
Retrospective Studies
Time Factors
Grant Support
ID/Acronym/Agency:
CA-41285/CA/NCI NIH HHS; CA28734-01/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antibiotics, Antineoplastic; 0/Naphthacenes; 147-94-4/Cytarabine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Acute myeloid leukaemia in childhood: clinical features and prognosis.
Next Document:  Diagnostic significance of detecting pseudo-Pelger-Huët anomalies and micro-megakaryocytes in myelod...